Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.62 |
| ▸ | MAPT | P10636 | 6/20 | 0.62 |
| ▸ | MEN1 | O00255 | 5/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | MAOA | P21397 | 5/20 | 0.59 |
| ▸ | EGFR | P00533 | 1/20 | 0.58 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.49 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.49 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.49 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.49 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | AR | P10275 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28683594 | 0.83 | MAOA (0.74) | CYP3A4MAPTMEN1KMT2AALOX15 | |
| SCHEMBL30346466 | 0.83 | MAOA (0.74) | CYP3A4MAPTMEN1KMT2AALOX15 | |
| SCHEMBL796920 | 0.81 | MAPT (0.58) | CYP3A4MAPTMEN1KMT2AALOX15 | |
| SCHEMBL10324199 | 0.78 | MGAM (0.56) | CYP3A4MAPTMEN1KMT2AALOX15 | |
| SCHEMBL1607111 | 0.77 | MEN1 (0.62) | CYP3A4MAPTMEN1KMT2AALOX15 | |
| SCHEMBL31344371 | 0.77 | MEN1 (0.62) | CYP3A4MAPTMEN1KMT2AALOX15 | |
| SCHEMBL17237774 | 0.77 | MEN1 (0.54) | CYP3A4MAPTMEN1KMT2AALOX15 | |
| SCHEMBL29432477 | 0.77 | MEN1 (1.00) | CYP3A4MAPTMEN1KMT2AALOX15 | |
| SCHEMBL290081 | 0.77 | MEN1 (1.00) | CYP3A4MAPTMEN1KMT2AALOX15 | |
| SCHEMBL1135434 | 0.75 | MEN1 (0.65) | CYP3A4MAPTMEN1KMT2AALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12053465-B2 | KCC2 expression enhancing compounds and uses thereof | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2024-08-06 | — | — | US | disclosed |
| US-11925622-B2 | Role of novel carbazole linked 1, 2, 3- triazole analogs in alleviating methylglyoxal-mediated late diabetic vascular complications | JAHAN HUMERA (PK) | 2024-03-12 | — | — | US | disclosed |
| US-20230079389-A1 | COMPOSITION FOR USE IN PREVENTION OR TREATMENT OF OESOPHAGEAL DISEASES LINKED TO EPITHELIAL BARRIER DEFECTS | THELIAL B.V. (NL) | 2023-03-16 | — | — | US | disclosed |
| US-20220378782-A1 | KCC2 EXPRESSION ENHANCING COMPOUNDS AND USES THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2022-12-01 | — | — | US | disclosed |
| US-11331313-B2 | KCC2 expression enhancing compounds and uses thereof | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2022-05-17 | — | — | US | disclosed |
| US-20200085817-A1 | KCC2 EXPRESSION ENHANCING COMPOUNDS AND USES THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2020-03-19 | — | — | US | disclosed |
| WO-2018217766-A1 | KCC2 EXPRESSION ENHANCING COMPOUNDS AND USES THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2018-11-29 | — | — | WO | disclosed |
| CN-107216303-A | Fluorine can draw fixed synthetic method | 北京盛诺基医药科技有限公司 | 2017-09-29 | — | — | CN | disclosed |
| CN-107158386-A | Prevent and treat the medicine of alopecia | 段新方 | 2017-09-15 | — | — | CN | disclosed |
| US-20160143878-A1 | ANTIBACTERIAL AGENT | JUNTENDO EDUCATIONAL FOUNDATION (JP) | 2016-05-26 | — | — | US | disclosed |
| US-20150322033-A1 | ANTIBACTERIAL AGENT | JUNTENDO EDUCATIONAL FOUNDATION (JP) | 2015-11-12 | — | — | US | disclosed |
| US-20120183587-A1 | FLAVONOL COMPOSITIONS | LINES, THOMAS CHRISTIAN (CH) | 2012-07-19 | — | — | US | disclosed |
| CN-102533892-A | Method for preparing high-activity benzopyran-4-one with flavones of sea buckthorn leaves through biotransformation | QINGHAI GENERAL HEALTH BIO SCIENCE CO LTD | 2012-07-04 | — | — | CN | disclosed |
| US-20070148185-A1 | Novel therapeutic target for protozoal diseases | VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160143878-A1 | ANTIBACTERIAL AGENT | MRPL21, Q6ZSR9, NQO2 | CYP3A4 647/4885MAPT 4732/4885MEN1 4060/4885 |
| US-11331313-B2 | KCC2 expression enhancing compounds and uses thereof | MECP2, SLC1A2, GRIN2C | CYP3A4 4721/4885MAPT 1725/4885MEN1 2772/4885 |
| US-20200085817-A1 | KCC2 EXPRESSION ENHANCING COMPOUNDS AND USES THEREOF | MECP2, SLC1A2, GRIN2C | CYP3A4 4721/4885MAPT 1725/4885MEN1 2772/4885 |
| US-20120183587-A1 | FLAVONOL COMPOSITIONS | CYP2F1, F3, TEAD3 | CYP3A4 403/4885MAPT 1698/4885MEN1 2383/4885 |
| US-20150322033-A1 | ANTIBACTERIAL AGENT | Q6ZSR9, MRPL21, NQO2 | CYP3A4 734/4885MAPT 4733/4885MEN1 4104/4885 |
| US-20220378782-A1 | KCC2 EXPRESSION ENHANCING COMPOUNDS AND USES THEREOF | MECP2, SLC1A2, GRIN2C | CYP3A4 4721/4885MAPT 1725/4885MEN1 2772/4885 |
| US-12053465-B2 | KCC2 expression enhancing compounds and uses thereof | MECP2, SLC1A2, GRIN2C | CYP3A4 4721/4885MAPT 1725/4885MEN1 2772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.